The Health Ministry was informed by the Danish pharmaceutic company, Novo Nordisk, about an expected shortage of Norditropin, a drug used to treat children who need growth hormone injections. The shortage will be felt in the second half of 2023.
To prevent a gap in the treatment of these children, the ministry contacted Pfizer, which produces Gentropin, asking it to increase its stock to cover for the shortage of Norditropin.
The Heatlh Ministry also updated the health funds and contacted the Pediatric Endocrinology Association in order for it to issue clinical guidelines for doctors to transfer patients to treatment with the replacement medication.